All the funding deals in the longevity biotech market
In our updated market reports, you will find everything you need
The longevity biotech market is attracting growing interest from investors across therapeutics, diagnostics, cellular rejuvenation, and age-related disease research.
We conducted deep research and collected 35 funding deals in the longevity biotech market from Q1 2024 to Q2 2026.
We refresh this page very often to add new longevity biotech funding deals and keep the information current.
Insights
- The longevity biotech market recorded about $2.6 billion across 35 deals from Q1 2024 to Q2 2026, but a few very large rounds generated most of the total.
- Retro Biosciences raised $1 billion in Q1 2025. This was the largest longevity biotech funding deal in the research by a wide margin.
- NewLimit raised $610 million across three rounds. The funding shows strong investor interest in epigenetic reprogramming and cellular rejuvenation.
- BioAge Labs raised $368 million through a Series D round and an IPO. BioAge Labs connects aging biology with obesity and metabolic disease treatments.
- Longevity therapeutics received much more capital than diagnostics. However, GlycanAge, NADMED, and Generation Lab show growing demand for biological-age testing.
- Animal longevity is becoming an important part of the longevity biotech market. Loyal raised $167 million across three rounds between 2024 and 2026.
- The longevity biotech market recorded more than $662 million across six disclosed deals during the first half of 2026.
- Cell rejuvenation, stem-cell restoration, and epigenetic reprogramming attracted several large rounds because these platforms may support multiple future treatments.
- Funding sizes in the longevity biotech market ranged from $1.2 million to $1 billion, showing activity across early-stage startups and established biotechnology companies.
Summary table of the funding deals for the longevity biotech market since 2024
We define the longevity biotech market as biotechnology companies developing therapeutics and diagnostics aimed at slowing or reversing biological aging.
It includes Longevity Therapeutics, Cell Rejuvenation Platforms, Senolytic Drug Developers, Epigenetic Reprogramming, Age Biomarker Companies, and Regenerative Longevity Therapies.
It excludes broader adjacent markets unless the product is built specifically for this use case.
We focused exclusively on pure players, defined as companies with at least 70–80% of their business directly tied to the longevity biotech market.
Our analysis has been done at a global level with a minimum funding threshold of $300k.
If you want a longer-term view, we also have a study of how funding activity in the longevity biotech market has changed over the years.
| Name | What they do | Amount in $ | Quarter | Source(s) |
|---|---|---|---|---|
| Rapalogix Health | Develops TORC1-based treatments for skin aging and cellular longevity. | $20.0M | Q2 2026 | Business Wire |
| Gero | Uses AI and human data to find drug targets for aging. | $17.0M | Q2 2026 | Business Wire |
| NewLimit | Develops epigenetic medicines that restore youthful cell function. | $435.0M | Q2 2026 | NewLimit, Fierce Biotech |
| Life Biosciences | Develops cellular rejuvenation therapies for diseases linked to aging. | $80.0M | Q2 2026 | Life Biosciences |
| HexemBio | Develops therapies that rejuvenate aging blood stem cells. | $10.4M | Q2 2026 | HexemBio |
| Loyal | Develops regulated medicines that extend healthy lifespan in dogs. | $100.0M | Q1 2026 | Business Wire |
| GlycanAge | Measures biological aging and inflammation using glycan biomarkers. | $8.7M | Q4 2025 | EU-Startups |
| Generation Lab | Measures biological aging across organ systems using blood data. | $11.0M | Q4 2025 | PR Newswire |
| NewLimit | Develops epigenetic medicines for cellular rejuvenation and liver repair. | $45.0M | Q4 2025 | MarketScreener |
| The Cat Health Company | Develops medicines that extend feline healthspan and treat age-related disease. | $1.2M | Q4 2025 | Longevity.Technology |
| cellvie | Develops mitochondria-based therapies for cellular energy failure. | $5.0M | Q3 2025 | cellvie |
| Jocasta Neuroscience | Develops Klotho protein therapies for cognitive decline. | $35.0M | Q3 2025 | PR Newswire |
| Circulate Health | Uses plasma exchange to improve healthspan and biological-age markers. | $12.0M | Q3 2025 | PR Newswire |
| Juvenescence | Develops medicines for aging mechanisms and age-related diseases. | $150.0M | Q2 2025 | StockTitan, MarketScreener |
| NewLimit | Develops epigenetic medicines that restore youthful cell function. | $130.0M | Q2 2025 | TechCrunch, Fierce Biotech |
| Loyal | Develops regulated medicines that extend healthy lifespan in dogs. | $22.0M | Q1 2025 | Business Wire |
| Junevity | Develops siRNA therapies that reset aged or damaged cells. | $10.0M | Q1 2025 | Business Wire |
| Retro Biosciences | Develops cellular reprogramming and plasma therapies for healthy lifespan. | $1,000.0M | Q1 2025 | Financial Times, TechCrunch |
| Cambrian Bio | Develops medicines targeting biological drivers of aging. | $23.0M | Q1 2025 | CB Insights, Channel Point Capital |
| Integrated Biosciences | Uses synthetic biology and AI to develop age-related disease drugs. | $17.2M | Q4 2024 | Integrated Biosciences |
| Arda Therapeutics | Develops therapies that remove harmful cells driving chronic disease. | $43.0M | Q4 2024 | Arda Therapeutics |
| clock.bio | Finds gene therapy targets for rejuvenation and longer healthspan. | $5.3M | Q4 2024 | Business Wire |
| Shift Bioscience | Uses AI cell models to identify safe rejuvenation genes. | $16.0M | Q4 2024 | Shift Bioscience |
| BioAge Labs | Develops metabolic disease drugs based on human aging biology. | $198.0M | Q3 2024 | BioSpace |
| Oisín Biotechnologies | Develops genetic medicines for frailty and age-related disease. | $15.0M | Q3 2024 | FirstWord Pharma |
| Human Longevity, Inc. | Provides AI-based precision longevity testing and preventive care. | $39.8M | Q3 2024 | PR Newswire |
| NADMED | Develops blood tests for NAD, glutathione, and cellular health. | $3.8M | Q3 2024 | Cision News |
| Rubedo Life Sciences | Develops drugs that remove senescent cells linked to aging. | $40.0M | Q2 2024 | Business Wire |
| Matter Bio | Develops therapies that protect genome integrity and extend healthspan. | $7.0M | Q2 2024 | PR Newswire |
| Vasa Therapeutics | Develops therapies for cardiovascular aging, frailty, and muscle loss. | $6.0M | Q1 2024 | PR Newswire |
| BioAge Labs | Develops metabolic disease drugs based on human aging biology. | $170.0M | Q1 2024 | Business Wire |
| GlycanAge | Measures biological aging and inflammation using glycan biomarkers. | $4.2M | Q1 2024 | GlycanAge |
| SENISCA | Develops RNA therapies for age-related diseases and cell senescence. | $4.7M | Q1 2024 | SENISCA |
| Loyal | Develops regulated medicines that extend healthy lifespan in dogs. | $45.0M | Q1 2024 | Business Wire |
| Aeovian Pharmaceuticals | Develops selective mTORC1 drugs for diseases linked to aging. | $50.0M | Q1 2024 | Hevolution Foundation |
Related blog posts
- Which companies are the most valued in the longevity biotech market?
- Is fundraising strong in the longevity biotech market right now?
- Which companies have raised the most funding in the longevity biotech market?
- What are the latest fundraising trends in the longevity biotech market?
